Texas Capital Bank Wealth Management Services Inc Purchases 5,452 Shares of Merck & Co., Inc. $MRK

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Texas Capital Bank Wealth Management Services Inc raised its position in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) by 239.6% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 7,727 shares of the company's stock after acquiring an additional 5,452 shares during the period. Texas Capital Bank Wealth Management Services Inc's holdings in Merck & Co., Inc. were worth $694,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. Foundation Wealth Management LLC PA lifted its stake in shares of Merck & Co., Inc. by 2.4% in the first quarter. Foundation Wealth Management LLC PA now owns 5,361 shares of the company's stock valued at $481,000 after buying an additional 127 shares during the period. Saiph Capital LLC lifted its stake in shares of Merck & Co., Inc. by 3.7% in the first quarter. Saiph Capital LLC now owns 3,565 shares of the company's stock valued at $320,000 after buying an additional 128 shares during the period. N.E.W. Advisory Services LLC lifted its stake in shares of Merck & Co., Inc. by 2.6% in the first quarter. N.E.W. Advisory Services LLC now owns 5,197 shares of the company's stock valued at $466,000 after buying an additional 130 shares during the period. Tilson Financial Group Inc. lifted its stake in shares of Merck & Co., Inc. by 2.7% in the first quarter. Tilson Financial Group Inc. now owns 4,965 shares of the company's stock valued at $446,000 after buying an additional 132 shares during the period. Finally, Perkins Coie Trust Co lifted its stake in shares of Merck & Co., Inc. by 2.3% in the first quarter. Perkins Coie Trust Co now owns 6,021 shares of the company's stock valued at $540,000 after buying an additional 136 shares during the period. 76.07% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

MRK has been the subject of several research reports. Morgan Stanley reduced their target price on shares of Merck & Co., Inc. from $99.00 to $98.00 and set an "equal weight" rating for the company in a research note on Thursday, July 10th. Wells Fargo & Company reduced their target price on shares of Merck & Co., Inc. from $97.00 to $90.00 and set an "equal weight" rating for the company in a research note on Wednesday, July 30th. Cantor Fitzgerald cut shares of Merck & Co., Inc. from an "overweight" rating to a "cautious" rating in a research note on Tuesday, May 20th. Wall Street Zen cut shares of Merck & Co., Inc. from a "strong-buy" rating to a "buy" rating in a research note on Friday, April 25th. Finally, Citigroup reiterated a "neutral" rating and issued a $84.00 target price (down previously from $115.00) on shares of Merck & Co., Inc. in a research note on Wednesday, May 14th. One equities research analyst has rated the stock with a sell rating, twelve have given a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Merck & Co., Inc. presently has an average rating of "Hold" and a consensus price target of $107.44.

Merck & Co., Inc. Price Performance

Shares of MRK opened at $84.21 on Tuesday. The stock has a market cap of $210.34 billion, a price-to-earnings ratio of 12.98, a P/E/G ratio of 0.89 and a beta of 0.38. The company has a quick ratio of 1.17, a current ratio of 1.42 and a debt-to-equity ratio of 0.69. Merck & Co., Inc. has a 12 month low of $73.31 and a 12 month high of $120.30. The company has a 50-day moving average price of $81.28 and a two-hundred day moving average price of $83.21.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last posted its quarterly earnings data on Tuesday, July 29th. The company reported $2.13 earnings per share for the quarter, topping the consensus estimate of $2.03 by $0.10. The company had revenue of $15.81 billion during the quarter, compared to analyst estimates of $15.92 billion. Merck & Co., Inc. had a net margin of 25.79% and a return on equity of 41.05%. Equities analysts predict that Merck & Co., Inc. will post 9.01 EPS for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, October 7th. Stockholders of record on Monday, September 15th will be issued a dividend of $0.81 per share. The ex-dividend date of this dividend is Monday, September 15th. This represents a $3.24 annualized dividend and a dividend yield of 3.8%. Merck & Co., Inc.'s dividend payout ratio (DPR) is presently 49.92%.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.